Novartis FDA Approves Foundation Medicine's Liquid Biopsy Test as CDx for Novartis' Tabrecta in NSCLC The blood-based test is the second Foundation Medicine assay approved to ID patients eligible for the drug due to mutations leading to MET exon 14 skipping. Pricey, But Available The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian. Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes. Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials. Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients. May 6, 2020 FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC Dec 4, 2019 FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray Nov 19, 2019 Double Mutations in PIK3CA Gene Increase Patient Sensitivity to Targeted Therapies, Study Finds Premium Nov 7, 2019 Colorectal Cancers Dial up Mutability in Response to Targeted Treatments Oct 21, 2019 SomaLogic Expands Agreement With Novartis Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Jun 18, 2019 Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms Premium May 24, 2019 FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug Feb 14, 2019 AbCellera, Novartis Partner on Antibody Drug Discovery Dec 7, 2018 Novartis Drug Shows Promise in PIK3CA Mutated Breast Cancer, Potential Utility of ctDNA Testing Premium Dec 6, 2018 Qiagen to Develop Companion Dx for Novartis Breast Cancer Drug Nov 13, 2018 Health Canada Approves Two BCR-ABL Tests Oct 30, 2018 Precision Oncology Highlights From ESMO 2018 Oct 17, 2018 Foundation Medicine, Novartis Partner to Develop CDx for Oncology Drugs Aug 1, 2018 New Lung Cell Type Linked to Cystic Fibrosis Emerges From Mouse, Human Cell Atlas Studies Jun 4, 2018 MolecularMD, Genoptix Ink Marketing Agreement for CDx to Novartis CML Drug Feb 6, 2018 Quest to Offer Thermo Fisher's Oncomine Dx Target Test Dec 27, 2017 MolecularMD Gets FDA Authorization for Companion Dx to Novartis CML Drug Nov 27, 2017 European Consortium Aims to Deliver New Tests, Therapies for Cardiovascular Diseases Premium Nov 7, 2017 Roche ALK Test Gains FDA Approval as CDx for Alecensa Load More Breaking News In Brief This Week: Illumina, Personalis, Proteomedix, and More Ancient DNA Details Population Dynamics Within Andean Tiwanaku Civilization Genomic Data Spanning 2K Years Gives Glimpse of Etruscan Origins, Population Changes People in the News: New Appointments at Hologic, Akoya Biosciences, Caris Life Sciences, More At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.